Recent Research Funding

We receive funding from a variety of sources that recognize the value of our high-impact research.

Brian Clemency, DO, MBA, FACEP, FAEMS

  • First Responders - Comprehensive Addiction and Recovery Act (FR-CARA). Brian Clemency (Co-Investigator), Joshua Lynch (Co-Investigator). Substance Abuse and Mental Health Administration. $45,000. 10/1/2019-9/1/2020.
  • Expansion of addiction treatment in the jail/prison system and OB/GYN practice settings. Brian Clemency (Co-Investigator), Joshua Lynch (Co-Investigator). Office of Alcoholism and Substance Abuse Services. $140,693. 4/1/2019-8/1/2019.
  • Expansion of addictions treatment and rapid referrals across Western New York. Brian Clemency (Co-Investigator), Joshua Lynch (Co-Investigator). Blue Cross Blue Shield Blue Fund. $197,000. 10/1/2018-12/1/2019.

Joshua Lynch, DO, EMT-P, FAAEM, FACEP

  • Expansion of addictions treatment and technical advisement across New York state. Joshua Lynch (Principal Investigator). New York State DOH. $55,050. 10/1/2019-8/1/2020.
  • First Responders - Comprehensive Addiction and Recovery Act (FR-CARA). Joshua Lynch (Co-Investigator), Brian Clemency (Co-Investigator). Substance Abuse and Mental Health Administration. $45,000. 10/1/2019-9/1/2020.
  • Expansion of addiction treatment in the jail/prison system and OB/GYN practice settings. Joshua Lynch (Co-Investigator), Brian Clemency (Co-Investigator). Office of Alcoholism and Substance Abuse Services. $140,693. 4/1/2019-8/1/2019.
  • Best practice model to screen for Hepatitis C and HIV. Joshua Lynch (Co-Investigator), Andrew Talal (Co-Investigator). Gilead Sciences. $315,000. 11/1/2018-9/1/2019.
  • Expansion of addictions treatment and rapid referrals across Western New York. Joshua Lynch (Co-Investigator), Brian Clemency (Co-Investigator). Blue Cross Blue Shield Blue Fund. $197,000. 10/1/2018-12/1/2019.